Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)

Commack, New York 11725

0 studies enrolling now · 6 studies all time

What they study most

Anaplastic Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related Tumors, BRAF V600E Mutation Positive, Hairy Cell Leukemia, Kidney Cancer, Leukemia, Leukemia, Hairy Cell, Metastatic Renal Cell Carcinoma, Pituitary, Pituitary Cancer, Pituitary Carcinoma

Studies at this site

• Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer — Running, not enrolling
• Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer — Running, not enrolling
• Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors — Completed
• A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia — Running, not enrolling
• Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers — Completed
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer — Completed